HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

PEPG — PepGen Inc.

PEPG (PepGen Inc.) stock: $5.22, $361.5M market cap, $104.8M cash, $256.7M EV, $415.6M fully diluted market cap. Next expected readout: Mar-27. Lead program: PGN-EDODM1 (Myotonic Dystrophy 1), Phase 2. Data from Fully Diluted's biotech stocks database.

What they do

PepGen Inc. (also referred to as “PepGen,” “we,” “our” or “us”) is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price
$5.22
Market cap
$361.5M
Cash
$104.8M
Enterprise value
$256.7M

Balance sheet

Cash$104.8M
Debt$0.0M
Net cash$104.8M
Enterprise value$256.7M
Basic shares69.3M shares
Fully diluted shares79.6M shares
Fully diluted market cap$415.6M
Cash per share$1.51
Quarterly burn$15.8M
Cash runway7.4 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.

Share structure

Common
69.3M
Pre-funded warrants
0.0M
Options
8.1M
RSUs
1.1M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
1.1M
FDSO
79.6M

Cap table as of 2026-08-02.

Price history

Loading PEPG daily closes…

Loading price history…

Next catalyst

PGN-EDODM1 · Now - Nov 30, 2026 · guided Now

Recently reported

PGN-EDODM1 Phase 2 Positive · 2026-11-10
FREEDOM2-DM1 · myotonic dystrophy 1
Primary: Correction of RNA mis-splicing in muscle tissue, measured as splicing correction on the 22-gene panel, in the 10 mg/kg multiple ascending dose cohort of FREEDOM2-DM1 — Mean splicing correction of 46.5% was observed at Week 13
· Five of six participants showed greater than 20% splicing correction and four having more than 50% splicing correction at Week 13; pooled placebo (n=4) mean splicing correction was 6.8% at Week 13
· Cohort enrolled eight participants, randomized 3:1 to PGN-EDODM1 (n=6) or placebo (n=2), four intravenous doses every four weeks; all eight completed the Week 16 assessment
· Video Hand Opening Time improved 4.3 seconds at Week 13 and 3.9 seconds at Week 16, an approximately 52.7% improvement at Week 16 (placebo improved 0.2 seconds at Week 16)
· Hand grip strength improved by approximately 16.2% at Week 16, a 6.3-point improvement in maximum predicted percent normal from baseline (placebo improved 0.9 points)
· Timed Up and Go improved by 8.5%, or 0.6 seconds, at Week 16 (placebo worsened 0.5 seconds); 10-Meter Walk/Run Test improved by 6.8%, or 0.4 seconds (placebo improved 0.2 seconds)
· 12.5 mg/kg cohort fully enrolled, results expected in the first half of 2027; interim 5 mg/kg FREEDOM-OLE clinical data and 10 mg/kg OLE safety data expected in January 2027
Safety: Generally well tolerated at 10 mg/kg; all treatment-emergent adverse events in the cohort were mild or moderate, the most commonly reported was nausea, and four mild renal TEAEs (transient albuminuria after the first dose) were reported with no evidence of cumulative renal toxicity over 16 weeks
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego